Shanghai Medicilon Inc. (SHA:688202)
62.97
-0.48 (-0.76%)
At close: Jan 22, 2026
Shanghai Medicilon Revenue
Shanghai Medicilon had revenue of 302.56M CNY in the quarter ending September 30, 2025, with 7.94% growth. This brings the company's revenue in the last twelve months to 1.08B, up 9.63% year-over-year. In the year 2024, Shanghai Medicilon had annual revenue of 1.04B, down -24.01%.
Revenue (ttm)
1.08B
Revenue Growth
+9.63%
P/S Ratio
7.68
Revenue / Employee
459.34K
Employees
2,349
Market Cap
8.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.04B | -327.89M | -24.01% |
| Dec 31, 2023 | 1.37B | -293.30M | -17.68% |
| Dec 31, 2022 | 1.66B | 491.67M | 42.12% |
| Dec 31, 2021 | 1.17B | 501.31M | 75.28% |
| Dec 31, 2020 | 665.96M | 216.56M | 48.19% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Anhui Huaheng Biotechnology | 2.83B |
| Suzhou Fengbei Biotech Stock | 2.81B |
| Nanjing Vazyme Biotech | 1.34B |
| Chengdu Kanghua Biological Products | 1.21B |
| Wuhan Keqian Biology Co.,Ltd | 1.01B |
| Jiangxi Fushine Pharmaceutical | 970.32M |
| Daan Gene | 765.48M |
| GemPharmatech | 752.70M |